ACET
−$204.6K
32,523 sh @ $6
ORBIMED ADVISORS LLC
10% Owner, Director · SEC CIK 1569821Advertisement
Buy track record
How this insider's open-market purchases have performed0%
of buys now in profit
0 up · 18 down
Avg return since buy−86.2%
Median return−89.9%
Best trade−49.2%
Worst trade−100.0%
Buys scored18 (+1 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+0.9%
56% won · 18 trades
After 3 months
−18.9%
28% won · 18 trades
After 6 months
−35.0%
6% won · 18 trades
After 12 months
−41.7%
0% won · 16 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2025 | ACET | $1 | $1.5M | +20% | −29.3% | −45.6% | −55.9% | — | −49.2% | |
| Oct 8, 2025 | ACET | $1 | $3.5M | +353% | −29.3% | −45.6% | −55.9% | — | −49.2% | |
| Jan 25, 2024 | ACET | $2 | $4.42M | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −80.9% | |
| Jan 25, 2024 | ACET | $2 | $581.3K | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −80.9% | |
| Jan 25, 2024 | ACET | $2 | $2.5M | +486% | −2.0% | −26.7% | −38.9% | −63.2% | −80.9% | |
| Jun 27, 2023 | ACET | $2 | $261.3K | +14% | +17.4% | −32.4% | −17.4% | −37.1% | −77.8% | |
| Jun 27, 2023 | ACET | $2 | $522.5K | +63% | +17.4% | −32.4% | −17.4% | −37.1% | −77.8% | |
| Jun 27, 2023 | ACET | $2 | $923.8K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −77.8% | |
| Jun 27, 2023 | ACET | $2 | $121.2K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −77.8% | |
| Feb 27, 2023 | PHGE | $0 | $85.3K | +12% | −7.8% | −11.9% | +9.7% | −38.1% | −99.0% | |
| Jul 28, 2021 | PHGE | — | $0 | +22% | −18.4% | −51.0% | −67.2% | −77.1% | −99.9% | |
| Dec 19, 2019 | PHGE | $9 | $31.2K | +0.2% | −9.5% | −34.5% | −40.1% | −41.0% | −100.0% | |
| Dec 18, 2019 | PHGE | $9 | $4.5K | — | +1.3% | −21.9% | −38.4% | −31.7% | −100.0% | |
| Dec 11, 2019 | PHGE | $9 | $48.2K | +0.2% | +2.6% | +9.8% | −33.7% | −29.5% | −100.0% | |
| Dec 10, 2019 | PHGE | $9 | $29.8K | +0.1% | +0.8% | +13.3% | −36.2% | −30.1% | −100.0% | |
| Dec 9, 2019 | PHGE | $9 | $52.1K | +0.3% | +7.4% | +15.6% | −45.5% | −30.9% | −100.0% | |
| Dec 6, 2019 | PHGE | $8 | $6.4K | — | +13.7% | +16.4% | −43.1% | −27.8% | −100.0% | |
| Dec 5, 2019 | PHGE | $8 | $27.2K | +0.1% | +20.6% | +24.0% | −37.8% | −23.4% | −100.0% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 18 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$16.62M
19 trades
Open-market sells
$25.05M
11 trades
Net flow
−$8.44M
Net selling
Total filings
43
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstACET
−$263.5K
40,416 sh @ $7
ACET
−$191.5K
29,319 sh @ $7
ACET
−$15.3K
2,400 sh @ $6
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $1.5M of their own money on 1.5M shares at $1, growing their stake 20%.
+$1.5M
1.5M sh @ $1
Advertisement
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $3.5M of their own money on 3.5M shares at $1, growing their stake 353%.
+$3.5M
3.5M sh @ $1
PHGE
+$2.26M
9.28M sh @ $0
PHGE
−$9.3K
24,344 sh @ $0
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $4.42M of their own money on 1.84M shares at $2, growing their stake 32%.
+$4.42M
1.84M sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $581.3K of their own money on 242,200 shares at $2, growing their stake 32%.
+$581.3K
242,200 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $2.5M of their own money on 1.04M shares at $2, growing their stake 486%.
+$2.5M
1.04M sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $261.3K of their own money on 125,000 shares at $2, growing their stake 14%.
+$261.3K
125,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $522.5K of their own money on 250,000 shares at $2, growing their stake 63%.
+$522.5K
250,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $923.8K of their own money on 442,000 shares at $2, growing their stake 8%.
+$923.8K
442,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $121.2K of their own money on 58,000 shares at $2, growing their stake 8%.
+$121.2K
58,000 sh @ $2
PHGE
Orbimed Israel Biofund Gp Limited Partnership, PHGE's 10% owner, spent $85.3K of their own money on 348,000 shares at $0, growing their stake 12%.
+$85.3K
348,000 sh @ $0
CMMB
−$889.7K
266,376 sh @ $3
CMMB
−$318.1K
70,524 sh @ $5
ACET
+$3M
214,285 sh @ $14
PHGE
Orbimed Israel Biofund Gp Limited Partnership, PHGE's 10% owner, spent $0 of their own money on 500,000 shares, growing their stake 22%.
+$0
500,000 sh
NMTR
−$19.35M
15.99M sh @ $1
NMTR
−$440.6K
319,255 sh @ $1
NMTR
−$1.14M
841,650 sh @ $1
NMTR
+$8.8K
12,500 sh @ $1
NMTR
+$12.1K
19,444 sh @ $1
CMMB
+$5M
288,170 sh @ $17
ACET
+$5.46M
420,299 sh @ $13
ACET
+$1.35M
104,050 sh @ $13
NVUS
−$2.23M
103,200 sh @ $22
NMTR
+$0
1.94M sh
Frequently asked questions
How is ORBIMED ADVISORS LLC's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from ORBIMED ADVISORS LLC's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.